MARKET

JAZZ

JAZZ

Jazz Pharmaceuticals Plc
NASDAQ
256.62
+0.06
+0.02%
Opening 15:43 08/10 EDT
OPEN
256.95
PREV CLOSE
256.56
HIGH
261.28
LOW
255.54
VOLUME
582.97K
TURNOVER
--
52 WEEK HIGH
265.05
52 WEEK LOW
105.00
MARKET CAP
16.66B
P/E (TTM)
17.55
1D
5D
1M
3M
1Y
5Y
1D
Jazz Pharmaceuticals: Buy Rating Reiterated as Actio Bioscience Acquisition and ABS-1230 Growth Potential Support Unchanged $307 Price Target
TipRanks · 9h ago
Zymeworks gains following addition to Citi catalyst watch
Seeking Alpha · 10h ago
Ami Fadia Reiterates Buy on Jazz Pharmaceuticals, Maintains $292 Price Target Following Actio Biosciences Acquisition
TipRanks · 12h ago
Jazz Pharmaceuticals to acquire Actio Biosciences for $1.32B
Seeking Alpha · 13h ago
Jazz Pharmaceuticals to Acquire Rare Epilepsy Specialist Actio
TipRanks · 14h ago
Jazz Pharmaceuticals To Acquire Developer Of Epilepsy Therapy Biotech Actio Biosciences For $820M Up Front And Up To $500M In Contingencies
Benzinga · 14h ago
Jazz Pharmaceuticals to acquire Actio Biosciences for $820M upfront
TipRanks · 14h ago
Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio
PR Newswire · 14h ago
More
About JAZZ
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.

Webull offers Jazz Pharmaceuticals PLC stock information, including NASDAQ: JAZZ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JAZZ stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JAZZ stock methods without spending real money on the virtual paper trading platform.